Anne S. Tsao, MD MBA

Peer-Reviewed Articles

1. Scherpereel A, Baas P, Nowak AK, Tsao AS, Fujimoto N, Peters S, Mansfield AS, Popat S, Bautista Aragon Y, Talbot T, Grossi F, Kowalski D, Kaplan MA, Cardona AF, Soomro R, Hu N, Lee A, Ip V, Hung YH, Zalcman G. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. J Clin Oncol:JCO2501328, 2026. e-Pub 2026. PMID: 41734361.
2. Li, H, Hong, L, Rocha, P, Bach, R, Solis Soto, LM, Rinsurongkawong, W, Zhang, B, Araujo, HA, Elamin, YY, Altan, M, Arrechedera, C, Zhou, J, Khan, KB, Lu, W, Young, E, Gay, CM, Cascone, T, Byers, LA, Skoulidis, F, Blumenschein, GR, Fossella, FV, Tsao, A, Vailati Negrao, M, Vokes, N, Wu, J, Tran, HT, Wistuba, II, Lee, JJ, Gibbons, DL, Vaporciyan, AA, Heymach, JV, Le, X, Zhang, J. MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer. Cancers 17(23), 2025. e-Pub 2025. PMID: 41375002.
3. Lin R, Chen M, Zhang X, Xu T, Xu T, Maguire RC, Corrigan KL, Koutroumpakis E, Chang JY, Lin SH, Chen AB, Nguyen Q, Gandhi SJ, Ning MS, Bronk J, Chun S, Ajdari A, Niedzielski JS, Yang J, Chen X, Pan T, Meng QH, Tsao AS, Deswal A, Mohan R, Liao Z. Bayesian Learning to Reduce Cardiac Risk of Patients With Locally Advanced Non-Small Cell Lung Cancer Based on Personalized Radiation Therapy Prescription. International Journal of Radiation Oncology Biology Physics, 2025. e-Pub 2025. PMID: 41365476.
4. Ozirmak Lermi, N, Molina Ayala, M, Hernandez, S, Lu, W, Khan, KB, Serrano, A, Lubo Julio, IC, Hamana Zorrilla, L, Tomczak, K, Barnes, S, Dou, J, Liang, Q, Zhang, S, Zhang, Q, Zhang, J, Xu, M, Woodman, SE, Wang, W, Virani, S, Sun, B, Subramanya, S, Song, X, Shaw, KR, Prabhakaran, S, Piubelli, ML, Mohammad, MM, Meric-Bernstam, F, Mendoza, MT, Mallampati, S, Little, L, Lang, W, Knafl, M, Khanduri, I, Gite, S, Arrechedera, C, Raso, G, Tang, X, Sanchez Espiridion, B, Weissferdt, A, Heymach, JV, Zhang, J, Sepesi, B, Cascone, T, Tsao, A, Altan, M, Mehran, RJ, Gibbons, DL, Wistuba, II, Haymaker, CL, Chen, K. Comparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samples. Nature communications 16(1), 2025. e-Pub 2025. PMID: 41006245.
5. Johnson, M, Smit, EF, Felip, E, Ramalingam, SS, Ahn, MJ, Tsao, A, Johnson, BE, Offin, MD, Hussein, M, Dagogo-Jack, I, Goldman, JW, Clarke, JM, Vailati Negrao, M, Sanborn, RE, Morgensztern, D, Usari, T, Wilner, KD, Alejandro, L, Rifi, N, Zhang, X, Riely, GJ. Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer. J Clin Oncol 43(35):3706-3713, 2025. e-Pub 2025. PMID: 41109959.
6. Tsao AS, Song Z, Ho AL, Mehnert JM, Ivy P, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Takebe N, Ajumally R, Silhavy J, Rahmanian S, Das B, Chen L, Karlovich C, Lococo JS, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T. JCO Precis Oncol 9:e2500119, 2025. e-Pub 2025. PMID: 41066729.
7. Riely, GJ, Ahn, MJ, Clarke, JM, Dagogo-Jack, I, Esper, R, Felip, E, Gelsomino, F, Goldman, JW, Hussein, M, Johnson, M, Marrone, KA, Morgensztern, D, Nadal, E, Vailati Negrao, M, Offin, MD, Provencio, M, Ramalingam, SS, Roof, L, Sanborn, RE, Smit, EF, Tsao, A, Usari, T, Alcasid, A, Wilner, KD, Tonkovyd, S, Zhang, X, Johnson, BE. Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC—A Brief Report. Journal of Thoracic Oncology 20(10):1538-1547, 2025. e-Pub 2025. PMID: 40480428.
8. Reuss JE, Lee PK, Mehran RJ, Hu C, Ke S, Jamali A, Najjar M, Niknafs N, Wehr J, Oner E, Meng Q, Pereira G, Hosseini-Nami S, Sausen M, Zahurak M, Battafarano RJ, Hales RK, Friedberg J, Sepesi B, Deutsch JS, Cottrell T, Taube J, Illei PB, Smith KN, Pardoll DM, Tsao AS, Brahmer JR, Anagnostou V, Forde PM. Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses. Nat Med 31(12):4097-4108, 2025. e-Pub 2025. PMID: 40921804.
9. Heeke, S, Gandhi, S, Tran, HT, Lam, VK, Byers, LA, Gibbons, DL, Gay, CM, Altan, M, Antonoff, MB, Le, X, Tu, J, Saad, M, Pek, M, Poh, J, Ngeow, KC, Tsao, A, Cascone, T, Vailati Negrao, M, Wu, J, Blumenschein, GR, Heymach, JV, Elamin, YY. Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA. JTO Clinical and Research Reports 6(4), 2025. e-Pub 2025. PMID: 40160974.
10. Tsao AS, Hsieh MH, Koczywas M, Tu J, Riess J, Tanvetyanon T, Ma BT, Zhao YQ, Redman MW, Edelman MJ, Gandara DR, Gray JE, Kelly KL. S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma. JTO Clin Res Rep 5(12):100738, 2024. e-Pub 2024. PMID: 39619274.
11. Roy-Chowdhuri S, Mani H, Fox AH, Tsao A, Sholl LM, Farjah F, Johnson BE, Osarogiagbon RU, Rivera MP, Silvestri GA, Smith RA, Wistuba II. The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancer. Cancer 130(24):4200-4212, 2024. e-Pub 2024. PMID: 39347608.
12. Xia Y, Wang K, Zhao J, Arter Z, Zhang Y, Zhou J, Lu Y, Zeng L, Du R, Owens JA, Elamin YY, Gay CM, Skoulidis F, Tsao AS, Lu C, Cascone T, Gibbons DL, Zhang J, Chen O, Mok KK, Nagasaka M, Li W, Heymach JV, Ignatius Ou SH, Li M, Le X. Receptor tyrosine kinase fusion-mediated resistance to EGFR-TKI in EGFR-mutant NSCLC: a multi-center analysis and literature review. J Thorac Oncol 20(4):465-474, 2024. e-Pub 2024. PMID: 39622411.
13. Skoulidis, F, Araujo, HA, Do, MT, Qian, Y, Sun, X, Cobo, AG, Le, JT, Montesion, M, Palmer, R, Jahchan, NS, Juan, J, Min, C, Yu, Y, Pan, X, Arbour, KC, Vokes, N, Schmidt, S, Molkentine, D, Owen, D, Memmott, R, Patil, P, Marmarelis, ME, Awad, MM, Murray, J, Hellyer, JA, Gainor, J, Dimou, A, Bestvina, CM, Shu, CA, Riess, JW, Blakely, CM, Pecot, CV, Mezquita, L, Tabbò, F, Scheffler, M, Digumarthy, S, Mooradian, MJ, Sacher, A, Lau, SC, Saltos, A, Rotow, JK, Johnson, RP, Liu, C, Stewart, TF, Goldberg, SB, Killam, J, Walther, Z, Schalper, K, Davies, KD, Woodcock, MG, Anagnostou, V, Marrone, KA, Forde, PM, Ricciuti, B, Venkatraman, D, Van Allen, EM, Cummings, AL, Goldman, JW, Shaish, H, Kier, M, Katz, S, Aggarwal, C, Ni, Y, Azok, J, Segal, J, Ritterhouse, LL, Neal, JW, Lacroix, L, Elamin, YY, Vailati Negrao, M, Le, X, Lam, VK, Lewis, WE, Kemp, HN, Carter, B, Roth, JA, Swisher, SG, Lee, R, Zhou, T, Poteete, A, Kong, Y, Takehara, T, Paula, AG, Parra Cuentas, ER, Behrens, C, Wistuba, II, Zhang, J, Blumenschein, GR, Gay, CM, Byers, LA, Gibbons, DL, Tsao, A, Lee, JJ, Bivona, T, Camidge, DR, Gray, J, Lieghl, N, Levy, BP, Brahmer, JR, Garassino, MC, Gandara, D, Garon, EB, Rizvi, NA, Scagliotti, G, Wolf, J, Planchard, D, Besse, B, Herbst, RS, Wakelee, HA, Pennell, N, Shaw, AT, Jänne, PA, Carbone, DP, Hellmann, MD, Rudin, CM, Albacker, LA, Mann, H, Zhu, Z, Lai, Z, Stewart, RA, Peters, S, Johnson, M, Wong, KK, Huang, A, Winslow, MM, Rosen, MJ, Winters, IP, Papadimitrakopoulou, VA, Cascone, T, Jewsbury, P, Heymach, JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 635(8038):462-471, 2024. e-Pub 2024. PMID: 39385035.
14. Zhou N, Leung CH, William WN Jr, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Tran HT, Wu J, Solis Soto LM, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer 12(10), 2024. e-Pub 2024. PMID: 39448200.
15. Pan, K, Owens, J, Elamin, YY, Lu, C, Routbort, MJ, Zhang, J, Fossella, FV, Vailati Negrao, M, Altan, M, Pozadzides, JV, Skoulidis, F, Tsao A, Cascone, T, Heymach, JV, Ostrin, EJ, Le X. Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations. J Thorac Oncol 19(10):1438-1448, 2024. e-Pub 2024. PMID: 38866326.
16. Wright CC, Triller MD, Tsao AS, Zajac SA, Segal C, Ninan EP, Rice JB, Cooper WO, Hagberg CA, Clemens MW. Strategies to Mitigate the Pandemic Aftermath on Perioperative Professionalism. Jt Comm J Qual Patient Saf 50(12):827-833, 2024. e-Pub 2024. PMID: 39505609.
17. Szlosarek PW, Creelan BC, Sarkodie T, Nolan L, Taylor P, Olevsky O, Grosso F, Cortinovis D, Chitnis M, Roy A, Gilligan D, Kindler H, Papadatos-Pastos D, Ceresoli GL, Mansfield AS, Tsao A, O'Byrne KJ, Nowak AK, Steele J, Sheaff M, Shiu CF, Kuo CL, Johnston A, Bomalaski J, Zauderer MG, Fennell DA, Group AS. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. JAMA Oncol 10(4):475-483, 2024. e-Pub 2024. PMID: 38358753.
18. Wright C, Tsao A, Triller M, Hagberg C. Navigating professionalism challenges: Impact on patient safety. Journal of Clinical Anesthesia 95:111427, 2024. e-Pub 2024. PMID: 38447258.
19. Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, Skoulidis F, Byers LA, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Gibbons DL, Park K, Rinsurongkawong W, Lee JJ, Gandara D, Behl D, Shu CA, Riess JW, Baik C, Wakelee HA, Vaporciyan AA, Heymach JV, Zhang J, Le X. BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC). J Thorac Oncol 19(3):500-506, 2024. e-Pub 2024. PMID: 38012986.
20. Zhang B, Lewis W, Stewart CA, Morris BB, Solis LM, Serrano A, Xi Y, Wang Q, Lopez ER, Concannon K, Heeke S, Tang X, Raso G, Cardnell RJ, Vokes N, Blumenschein G, Elamin Y, Fosella F, Tsao A, Skoulidis F, Hume CB, Sasak K, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Tran H, Zhang J, Gibbons D, Vaporciyan A, Wang J, Park K, Heymach JV, Byers LA, Gay CM, Le X. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets. JTO Clin Res Rep 5(2):100623, 2024. e-Pub 2024. PMID: 38357092.
21. Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussein M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BE. A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer. Future Oncol 20(16):1047-1055, 2024. e-Pub 2024. PMID: 38357801.
22. Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet, 2023. e-Pub 2023. PMID: 37478883.
23. Deboever N, Zhou N, McGrail DJ, Tomczak K, Oliva JL, Feldman HA, Parra E, Zhang J, Lee PP, Antonoff MB, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Swisher SS, Vaporciyan AA, Altan M, Weissferdt A, Tsao AS, Haymaker CL, Sepesi B. Radiographic response to neoadjuvant therapy in pleural mesothelioma should serve as a guide for patient selection for cytoreductive operations. Front Oncol 13:1216999, 2023. e-Pub 2023. PMID: 37637041.
24. Wang K, Du R, Roy-Chowdhuri S, Li ZT, Hong L, Vokes N, Elamin YY, Hume CB, Skoulidis F, Gay CM, Blumenschein G, Fossella FV, Tsao A, Zhang J, Karachaliou N, O'Brate A, Gann CN, Lewis J, Rinsurongkawong W, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Altan M, Le X. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. JTO Clin Res Rep 4(8):100533, 2023. e-Pub 2023. PMID: 37649681.
25. Zhou, N, Bell, CS, Feldman, HA, Haymaker, CL, Hofstetter, WL, Tsao, A, Mehran, RJ, Rice, DC, Sepesi, B, Tomczak, K, Weissferdt, A, Parra Cuentas, ER, Zhang, J, Lee, PP, Rajaram, R, Vaporciyan, AA. Tumor thickness in mesothelioma predicts differential response to neoadjuvant therapy and survival. Journal of Thoracic and Cardiovascular Surgery 166(2):362-371.e9, 2023. e-Pub 2023. PMID: 36737380.
26. Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussain M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BE. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol 41(21):JCO2300774, 2023. e-Pub 2023. PMID: 37270692.
27. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
28. Negrao MV, Papadimitrakopoulou VA, Price AC, Tam AL, Furqan M, Laroia ST, Massarelli E, Pacheco J, Heymach JV, Tsao AS, Walker GV, Vora L, Mauro D, Kelley H, Wooldridge JE, Krieg AM, Niu J. Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC. JTO Clin Res Rep 4(3):100423, 2023. e-Pub 2023. PMID: 36925644.
29. Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer 174:112-117, 2022. e-Pub 2022. PMID: 36371941.
30. Sepesi B, Zhou N, William WN, Lin HY, Leung CH, Weissferdt A, Mitchell KG, Pataer A, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Negrao MV, Tsao AS, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 164(5):1327-1337, 2022. e-Pub 2022. PMID: 35190177.
31. Hui D, Puac V, Shelal Z, Dev R, Hanneman SK, Jennings K, Ma H, Urbauer DL, Shete S, Fossella F, Liao Z, Blumenschein G, Chang JY, O'Reilly M, Gandhi SJ, Tsao A, Mahler DA, Bruera E. Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial. Lancet Oncol 23(10):1321-1331, 2022. e-Pub 2022. PMID: 36087590.
32. Lazar Neto F, Sousa LG, Lewis WE, Glisson B, Heymach JV, Tsao AS, Ferrarotto R. Outcomes of Critically Ill Lung Cancer Patients Initiating Targeted Therapy or Immunotherapy in the Intensive Care Unit: A Single-Center Report. J Intensive Care Med 37(8):8850666211061312, 2022. e-Pub 2022. PMID: 34787022.
33. Carbone M, Pass HI, Ak G, Alexander HR, Baas P, Baumann F, Blakely AM, Bueno R, Bzura A, Cardillo G, Churpek JE, Dianzani I, De Rienzo A, Emi M, Emri S, Felley-Bosco E, Fennell DA, Flores RM, Grosso F, Hayward NK, Hesdorffer M, Hoang CD, Johansson PA, Kindler HL, Kittaneh M, Krausz T, Mansfield A, Metintas M, Minaai M, Mutti L, Nielsen M, O'Byrne K, Opitz I, Pastorino S, Pentimalli F, de Perrot M, Pritchard A, Ripley RT, Robinson B, Rusch V, Taioli E, Takinishi Y, Tanji M, Tsao AS, Tuncer AM, Walpole S, Wolf A, Yang H, Yoshikawa Y, Zolondick A, Schrump DS, Hassan R. Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. J Thorac Oncol 17(7):873-889, 2022. e-Pub 2022. PMID: 35462085.
34. Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell 40(7):754-767.e6, 2022. e-Pub 2022. PMID: 35820397.
35. Scherpereel A, Antonia S, Bautista Y, Grossi F, Kowalski D, Zalcman G, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Sun X, Lawrance R, Zhang X, Daumont MJ, Bennett B, McKenna M, Baas P. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung Cancer 167:8-16, 2022. e-Pub 2022. PMID: 35367910.
36. Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, Nowak AK, Fujimoto N, Tsao AS, Mansfield AS, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol 33(5):488-499, 2022. e-Pub 2022. PMID: 35124183.
37. Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol 40(7):702-709, 2022. e-Pub 2022. PMID: 34550757.
38. Riely GJ, Ahn MJ, Felip E, Ramalingam SS, Smit EF, Tsao AS, Alcasid A, Usari T, Wissel PS, Wilner KD, Johnson BE. Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study design. Future Oncol 18(7):781-791, 2022. e-Pub 2022. PMID: 34918546.
39. Tsao AS, Pass HI, Rimner A, Mansfield AS. New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options. J Clin Oncol 40(6):JCO2101567, 2022. e-Pub 2022. PMID: 34985934.
40. Zhou N, Rice DC, Tsao AS, Lee PP, Haymaker CL, Corsini EM, Antonoff MB, Hofstetter WL, Rajaram R, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Mehran RJ, Sepesi B. Extrapleural Pneumonectomy versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma. Ann Thorac Surg 113(1):200-208, 2022. e-Pub 2022. PMID: 33971174.
41. Lin SH, Lin HY, Verma V, Xu-Welliver M, Thall PF, Yao L, Kim PY, Gombos DS, Kawedia JD, Komaki R, Gomez DR, Nguyen QN, O'Reilly MS, Lu C, Fossella FV, Skoulidis F, Zhang J, Tsao AS, Heymach JV, Blumenschein GR. Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun 30:100514, 2022. e-Pub 2022. PMID: 35051703.
42. Le X, Hong L, Hensel C, Chen R, Kemp H, Coleman N, Ciunci CA, Liu SV, Negrao MV, Yen J, Xia X, Scheuenpflug J, Stroh C, Juraeva D, Tsao A, Hong D, Raymond V, Paik P, Zhang J, Heymach JV. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO Precis Oncol 5:1802-1812, 2021. e-Pub 2021. PMID: 34957368.
43. Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, Barreto DS, Robichaux JP, Reuben A, Cascone T, Gay CM, Mitchell KG, Hong L, Rinsurongkawong W, Roth JA, Swisher SG, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Singal G, Miller VA, Alexander B, Frampton G, Albacker LA, Shames D, Zhang J, Heymach JV. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer 9(8), 2021. e-Pub 2021. PMID: 34376553.
44. Tran HT, Lam VK, Elamin YY, Hong L, Colen R, Elshafeey NA, Hassan ISA, Altan M, Blumenschein GR, Rinsurongkawong W, Rivera MJ, Vasquez ME, Carter BW, Byers LE, Tsao AS, Gibbons DL, Fossella F, Glisson BS, Zhang J, Heymach JV. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol 5:1241-1249, 2021. e-Pub 2021. PMID: 34377884.
45. Riely GJ, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West HL, Mekhail T, Gentzler RD, Nguyen D, Vincent S, Zhang S, Lin J, Bunn V, Jin S, Li S, Jänne PA. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discov 11(7):1688-1699, 2021. e-Pub 2021. PMID: 33632775.
46. Augustyn A, Adams DL, He J, Qiao Y, Verma V, Liao Z, Tang CM, Heymach JV, Tsao AS, Lin SH. Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. Clin Lung Cancer 22(3):1525-7304, 2021. e-Pub 2021. PMID: 32798130.
47. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
48. Tam AL, Papadimitrakopoulou V, Wistuba II, Tsao, AS AS, Lee JJ, Ensor JE, Kim ES. A Team-Science Approach to Personalized Cancer Care:. Journal of Thoracic Oncology 76(2):155.e25-155.e34, 2021. e-Pub 2021. PMID: 33268083.
49. Parra ER, Zhai J, Tamegnon A, Zhou N, Pandurengan RK, Barreto C, Jiang M, Rice DC, Creasy C, Vaporciyan AA, Hofstetter WL, Tsao AS, Wistuba II, Sepesi B, Haymaker C. Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues. Sci Rep 11(1):4530, 2021. e-Pub 2021. PMID: 33633208.
50. Tam AL, Papadimitrakopoulou V, Wistuba II, Lee JJ, Ensor JE, Kim ES, Kalhor N, Blumenschein GR, Tsao AS, Heymach JV, Herbst RS, Hicks ME, Hong WK, Gupta S. The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials. Clin Radiol 76(2):155.e25-155.e34, 2021. e-Pub 2021. PMID: 33268083.
51. Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB, Lin SH, Chang JY, Tsao A, Gay CM, Zhu XR, Zhang X, Heymach JV, Fossella FV, Lu C, Nguyen QN, Liao Z. Toxicity and Survival after Intensity-Modulated Proton Therapy (IMPT) versus Passive Scattering Proton Therapy (PSPT) for Non-Small Cell Lung Cancer. J Thorac Oncol, 2021. e-Pub 2021. PMID: 33198942.
52. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397(10272):375-386, 2021. e-Pub 2021. PMID: 33485464.
53. Milbury K, Li Y, Durrani S, Liao Z, Tsao AS, Carmack C, Cohen L, Bruera E. A Mindfulness-Based Intervention as a Supportive Care Strategy for Patients with Metastatic Non-Small Cell Lung Cancer and their Spouses: Results of a 3-Arm Pilot Randomized Controlled Trial. Oncologist 25(11):e1794-e1802, 2020. e-Pub 2020. PMID: 32621630.
54. Gay CM, Zhou Y, Lee JJ, Tang XM, Lu W, Wistuba II, Ferrarotto R, Gibbons DL, Glisson BS, Kies MS, Simon GR, Heymach JV, Tsao AS. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist 25(10):1457-1463, 2020. e-Pub 2020. PMID: 32608142.
55. Chen R, Lee WC, Fujimoto J, Li J, Hu X, Mehran R, Rice D, Swisher SG, Sepesi B, Tran HT, Chow CW, Little LD, Gumbs C, Haymaker C, Heymach JV, Wistuba II, Lee JJ, Futreal PA, Zhang J, Reuben A, Tsao AS, Zhang J. Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. Clin Cancer Res 26(20):5477-5486, 2020. e-Pub 2020. PMID: 32816946.
56. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol 15(9):1449-1459, 2020. e-Pub 2020. PMID: 32389639.
57. Rajaram R, Correa AM, Xu T, Nguyen QN, Antonoff MB, Rice D, Mehran R, Roth J, Walsh G, Swisher S, Hofstetter WL, Vaporciyan A, Cascone T, Tsao AS, Papadimitrakopoulou VA, Gandhi S, Liao Z, Sepesi B. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clin Lung Cancer 21(4):e294-e301, 2020. e-Pub 2020. PMID: 32089476.
58. Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res 26(14):3525-3536, 2020. e-Pub 2020. PMID: 32193228.
59. Friedberg JS, Culligan MJ, Tsao AS, Rusch V, Adusumilli PS, Sepesi B, Pass HI, Bueno R, Burt B, Sugarbaker DJ, de Perrot M, Adjei AA, Hirsch FR, Malik SM, Harpole DJ. Reply to Waller et al. Standardizing Surgical Treatment for Mesothelioma. J Thorac Oncol 15(5):e75-e77, 2020. e-Pub 2020. PMID: 32340682.
60. Kris MG, Faivre-Finn C, Kordbacheh T, Chaft J, Luo J, Tsao A, Swisher S. Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. Am Soc Clin Oncol Educ Book 40:1-12, 2020. e-Pub 2020. PMID: 32298162.
61. Moding EJ, Liu Y, Nabet BY, Chabon JJ, Chaudhuri AA, Hui AB, Bonilla RF, Ko RB, Yoo CH, Gojenola L, Jones CD, He J, Qiao Y, Xu T, Heymach JV, Tsao A, Liao Z, Gomez DR, Das M, Padda SK, Ramchandran KJ, Neal JW, Wakelee HA, Loo BW, Lin SH, Alizadeh AA, Diehn M. Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. Nat Cancer 1(2):176-183, 2020. e-Pub 2020. PMID: 34505064.
62. Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol 15(2):248-257, 2020. e-Pub 2020. PMID: 31778797.
63. Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS. Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. J Thorac Oncol 14(10):1704-1717, 2019. e-Pub 2019. PMID: 31260832.
64. Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Clin Oncol 37(28):2537-2547, 2019. e-Pub 2019. PMID: 31386610.
65. Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AK. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol 14(10):1718-1731, 2019. e-Pub 2019. PMID: 31470129.
66. Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin 69(5):402-429, 2019. e-Pub 2019. PMID: 31283845.
67. Nelson DB, Rice DC, Mitchell KG, Tsao AS, Gomez DR, Sepesi B, Mehran RJ. Return to intended oncologic treatment after surgery for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 158(3):924-929, 2019. e-Pub 2019. PMID: 31430846.
68. Friedberg JS, Culligan MJ, Tsao AS, Rusch V, Sepesi B, Pass HI, Bueno R, Burt B, Sugarbaker DJ, de Perrot M, Adjei AA, Adusumilli PS, Hirsch FR, Malik SM, Harpole DJ. A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce. J Thorac Oncol 14(8):1343-1353, 2019. e-Pub 2019. PMID: 31136816.
69. Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, Ceresoli GL, Taylor P, Orlandi F, Fennell DA, Novello S, Scherpereel A, Kuribayashi K, Cedres S, Sørensen JB, Pavlakis N, Reck M, Velema D, von Wangenheim U, Kim M, Barrueco J, Tsao AS. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med 7(7):569-580, 2019. e-Pub 2019. PMID: 31103412.
70. Gomez DR, Rimner A, Simone CB, Cho BCJ, de Perrot M, Adjei AA, Bueno R, Gill RR, Harpole DH, Hesdorffer M, Hirsch FR, Jackson AA, Pass HI, Rice DC, Rusch VW, Tsao AS, Yorke E, Rosenzweig K. The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol 14(7):1172-1183, 2019. e-Pub 2019. PMID: 31125736.
71. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol 37(18):1558-1565, 2019. e-Pub 2019. PMID: 31067138.
72. Nelson DB, Rice DC, Mitchell KG, Tsao AS, Vaporciyan AA, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Gomez DR, Mehran RJ, Sepesi B. Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database. J Thorac Dis 11(4):1269-1278, 2019. e-Pub 2019. PMID: 31179069.
73. Tsao A, Nakano T, Nowak AK, Popat S, Scagliotti GV, Heymach J. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. Semin Oncol 46(2):145-154, 2019. e-Pub 2019. PMID: 31280996.
74. Forde PM, Scherpereel A, Tsao AS. Use of Immune Checkpoint Inhibitors in Mesothelioma. Curr Treat Options Oncol 20(2):18, 2019. e-Pub 2019. PMID: 30762130.
75. Tsao AS, Jolly S, Lee JM. Updates in Local-Regionally Advanced Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book 39:553-562, 2019. e-Pub 2019. PMID: 31099691.
76. Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J, Network TR, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov 8(12):1548-1565, 2018. e-Pub 2018. PMID: 30322867.
77. Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol 13(11):1655-1667, 2018. e-Pub 2018. PMID: 30266660.
78. Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R. Scientific Advances and New Frontiers in Mesothelioma Therapeutics. J Thorac Oncol 13(9):1269-1283, 2018. e-Pub 2018. PMID: 29966799.
79. Tsao AS, Gladish GW, Gill RR. Revised Modified RECIST Criteria in Malignant Pleural Mesothelioma (Version 1.1): A Step Forward in a Long Race. J Thorac Oncol 13(7):871-873, 2018. e-Pub 2018. PMID: 29935841.
80. Reck M, Garassino MC, Imbimbo M, Shepherd FA, Socinski MA, Shih JY, Tsao AS, Lee P, Winfree KB, Sashegyi A, Cheng R, Varea R, Levy B, Garon E. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer 120:62-69, 2018. e-Pub 2018. PMID: 29748017.
81. Reck M, Garassino MC, Imbimbo M, Shepherd FA, Socinski M, Shih J, Tsao AS, Lee P, Winfree KB, Sashegyi A, Cheng R, Varea R, Levy B, Garon E. Anti-angiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer. Lung Cancer, 2018. e-Pub 2018. PMID: 29748017.
82. Nelson DB, Rice DC, Niu J, Atay SM, Vaporciyan AA, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Tsao AS, Gomez DR, Giordano SH, Mehran RJ, Sepesi B. Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma. Eur J Cardiothorac Surg 53(5):960-966, 2018. e-Pub 2018. PMID: 29211849.
83. William WN, Tsao AS, Feng L, Ginsberg L, Lee JJ, Kies M, Glisson B, Kim E. Single arm. phase 2 study of cisplatin, docetaxel, and erlotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinomas. The Oncologist 23(5):526-e49, 2018. e-Pub 2018. PMID: 29371473.
84. Lyman GH, Balaban E, Diaz M, Ferris A, Tsao AS, Voest E, Zon R, Francisco M, Green S, Sherwood S, Harvey RD, Schilsky RL. American Society of Clinical Oncology Statement: Biosimilars in Oncology. J Clin Oncol 36(12):1260-1265, 2018. e-Pub 2018. PMID: 29443651.
85. Lyman G, Balaban E, Diaz M, Ferris A, Tsao AS, Voest E, Zon R, Francisco M, Green S, Sherwood S, Harvey* R, Schilsky RL. American Society of Clinical Oncology Position Statement: Biosimilars in Oncology. Journal of Clinical Oncology 20(36):1260-1265, 2018. e-Pub 2018. PMID: 29443651.
86. Milbury K, Engle R, Tsao AS, Liao Z, Owens A, Chaoul A, Bruera E, Cohen L. Pilot Testing of a Brief Couple-Based Mind-Body Intervention for Patients With Metastatic Non-Small Cell Lung Cancer and Their Partners. J Pain Symptom Manage 55(3):953-961, 2018. e-Pub 2018. PMID: 29208478.
87. Jeter MD, Gomez D, Nguyen QN, Komaki R, Zhang X, Zhu X, O'Reilly M, Fossella FV, Xu T, Wei X, Wang H, Yang W, Tsao AS, Mohan R, Liao Z. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Int J Radiat Oncol Biol Phys 100(3):730-737, 2018. e-Pub 2018. PMID: 29248169.
88. Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, Leiserson MDM, Sethi G, Lu C, Ryan M, Su X, Cherniack AD, Robertson G, Akbani R, Spellman P, Weinstein JN, Hayes DN, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC, Atlas Network CG, Fujimoto J, Scapulatempo-Neto C, Moreira AL, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Gokmen-Polar Y, Badve S, Rajan A, Ströbel P, Girard N, Tsao MS, Marx A, Tsao AS, Loehrer PJ. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell 33(2):244-258.e10, 2018. e-Pub 2018. PMID: 29438696.
89. Tsao AS, Lin H, Carter BW, Lee JJ, Rice D, Vaporcyan A, Swisher S, Mehran R, Heymach J, Nilsson M, Fan Y, Nunez M, Diao L, Wang J, Fujimoto J, Wistuba II, Hong WK. Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. J Thorac Oncol 13(2):246-257, 2018. e-Pub 2018. PMID: 29313814.
90. Milbury K, Tsao AS, Liao Z, Owns A, Engle R, Gonzalez EA, Bruera E, Cohen L. A research protocol for a pilot randomized controlled trial designed to examine the feasibility of a couple-based mind-body intervention for patients with metastatic lung cancer and their partners. Pilot Feasibility Stud 4:37, 2018. e-Pub 2018. PMID: 29416870.
91. Zauderer MG, Tsao AS, Dao T, Panageas K, Lai WV, Rimner A, Rusch VW, Adusumilli PS, Ginsberg MS, Gomez D, Rice D, Mehran R, Scheinberg DA, Krug LM. A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analog Peptide Vaccine, after Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res 23(24):7483-7489, 2017. e-Pub 2017. PMID: 28972039.
92. Tsao AS, Wistuba I, Xia D, Byers L, Diao L, Wang J, Papadimitrakopoulou V, Tang X, Lu W, Kadara H, Grigoryev DN, Selvan ME, Gumus ZH, Tan Z, Zhang S, Nilsson M, Heymach JV. Germline and Somatic Smoothened Mutations in Non-Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib. JCO Precis Oncol 1:1-10, 2017. e-Pub 2017. PMID: 35172522.
93. Reck M, Paz-Ares L, Bidoli P, Cappuzzo D, Dakhil S, Moro-Sibilot D, Borghaei H, Johnson M, Jotte R, Pennell N, Shepherd F, Tsao AS, Thomas M, Carter G, Chan-Diehl F, Alexandris E, Lee P, Zimmermann A, Treat J, Sashegyi A, Perol M. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung Cancer, 2017. e-Pub 2017. PMID: 29191593.
94. Nelson DB, Rice DC, Niu J, Atay S, Vaporciyan AA, Antonoff M, Hofstetter WL, LWalsh G, Swisher SG, Roth JA, Tsao AS, Gomez D, Giordano SH, RezaMehran, Sepesi B. Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. Journal of Clinical Oncology 35(29):3354-3362, 2017. e-Pub 2017. PMID: 28817374.
95. Scagliotti GV, Gaafar R, Nowak AK, Reck M, Tsao AS, van Meerbeeck J, Vogelzang NJ, Nakano T, von Wangenheim U, Velema D, Morsli N, Popat S. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. Clin Lung Cancer 18(5):589-593, 2017. e-Pub 2017. PMID: 28690011.
96. Maio M, Scherpereel A, Calabrò L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol 18(9):1261-1273, 2017. e-Pub 2017. PMID: 28729154.
97. Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol 12(8):1183-1209, 2017. e-Pub 2017. PMID: 28579481.
98. Reck M, Paz-Ares L, Bidoli P, Cappuzzo F, Dakhil S, Moro-Sibilot D, Borghaei H, Johnson M, Jotte R, Pennell NA, Shepherd FA, Tsao AS, Thomas M, Carter GC, Chan-Diehl F, Alexandris E, Lee P, Zimmermann A, Sashegyi A, Pérol M. Outcomes in patients with aggressive or refractory disease from REVEL, a randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung Cancer 112:181-187, 2017. e-Pub 2017. PMID: 29191593.
99. Tsao AS, Moon J, Wistuba I, Vogelzang N, Kalemkerian G, Redman M, Gandara D, Kelly K. Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). Journal of Thoracic Oncology 12(8):1299-1308, 2017. e-Pub 2017. PMID: 28599887.
100. Soo RA, A Stone EC, Cummings K, Jett JR, Field JK, M Groen HJ, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu Y, Higgins K, Senan S, Solomon B, Kim D, Johnson M, H Yang JC, Sequist LV, Shaw AT, Ahn M, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes M, Faivre-Finn C, Rudin C, Tsao AS, Bass P, Kelly R, Leighl N, Scagliotti G, Gandara D, Hirsch F, Spigel D. Scientific Advances in Thoracic Oncology 2016. Journal of Thoracic Oncology 12(8):1183-1209, 2017. e-Pub 2017. PMID: 28579481.
101. Bekaii-Saab T, Goel S, Dickerson A, Von Roenn J, Thompson MA, Tsao AS. Competitive Funding Strategies for the Conquer Cancer Foundation of ASCO. J Oncol Pract 13(1):e62-e67, 2017. e-Pub 2017. PMID: 27875070.
102. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17(12):1672-1682, 2016. e-Pub 2016. PMID: 27789196.
103. Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao AS, Woodard GA, Yang H, Malik S. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol 11(8):1246-62, 2016. e-Pub 2016. PMID: 27453164.
104. Rimner A, Zauderer MG, Gomez DR, Adusumilli PS, Parhar PK, Wu AJ, Woo KM, Shen R, Ginsberg MS, Yorke ED, Rice DC, Tsao AS, Rosenzweig KE, Rusch VW, Krug LM. Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. J Clin Oncol 34(23):2761-8, 2016. e-Pub 2016. PMID: 27325859.
105. Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE 2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with advanced Non-Small Cell Lung Cancer. J Clin Oncol 34(30):3638-3647, 2016. e-Pub 2016. PMID: 27480147.
106. Hui D, Kilgore K, Frisbee-Hume S, Park M, Tsao AS, Delgado Guay M, Lu C, William W, Pisters K, Eapen G, Fossella F, Amin S, Bruera E. Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial. J Pain Symptom Manage 52(1):8-16.e1, 2016. e-Pub 2016. PMID: 27330023.
107. Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015. J Thorac Oncol 11(5):613-38, 2016. e-Pub 2016. PMID: 27013409.
108. Tsao AS, Papadimitrakopoulou V, Lin H, Guo M, Lee JJ, Holsinger FC, Hong WK, Sturgis EM. Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners. Infect Agent Cancer 11:21, 2016. e-Pub 2016. PMID: 27123042.
109. Lou Y, Pecot CV, Tran HT, DeVito VJ, Tang XM, Heymach JV, Luthra R, Wistuba II, Zuo Z, Tsao AS. Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients with Lung Adenocarcinoma. Clin Lung Cancer 17(2):e5-11, 2016. e-Pub 2016. PMID: 26700910.
110. Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, Öhman R, Plummer R, Eberhardt WE, Fukuoka K, Gaafar RM, Lafitte JJ, Hillerdal G, Chu Q, Buikhuisen WA, Lubiniecki GM, Sun X, Smith M, Baas P. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 16(4):447-56, 2015. e-Pub 2015. PMID: 25800891.
111. Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, Wozniak AJ, Gandara DR. SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM). J Thorac Oncol 10(2):387-91, 2015. e-Pub 2015. PMID: 25611229.
112. Chance WW, Rice DC, Allen PK, Tsao AS, Fontanilla HP, Liao Z, Chang JY, Tang C, Pan HY, Welsh JW, Mehran RJ, Gomez DR. Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys 91(1):149-56, 2015. e-Pub 2015. PMID: 25442335.
113. Tsao AS. Current Readings: Window-of-opportunity trials for thoracic malignancies. Semin Thorac Cardiovasc Surg 26(4):323-30, 2014. e-Pub 2014. PMID: 25837547.
114. Gomez D, Tsao AS. Local and systemic therapies for malignant pleural mesothelioma. Curr Treat Options Oncol 15(4):683-99, 2014. e-Pub 2014. PMID: 25266654.
115. Riquelme E, Suraokar MB, Rodriguez J, Mino B, Lin HY, Rice DC, Tsao AS, Wistuba II. Frequent co-amplification and co-operation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma. J Thorac Oncol 9(7):998-1007, 2014. e-Pub 2014. PMID: 24926545.
116. Suraokar MB, Nunez MI, Diao L, Chow CW, Kim D, Behrens C, Lin H, Lee S, Raso G, Moran C, Rice D, Mehran R, Lee JJ, Pass HI, Wang J, Momin AA, James BP, Corvalan A, Coombes K, Tsao AS, Wistuba II. Expression Profiling Stratifies Mesothelioma Tumors and Signifies Deregulation of Spindle Checkpoint Pathway and Microtubule Network with Therapeutic Implications. Ann Oncol 25(6):1184-92, 2014. e-Pub 2014. PMID: 24669013.
117. Tsao AS, Harun N, Fujimoto J, Devito V, Lee JJ, Kuhn E, Mehran R, Rice D, Moran C, Hong WK, Shen L, Suraokar M, Wistuba I. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Ann Diagn Pathol 18(3):140-5, 2014. e-Pub 2014. PMID: 24747001.
118. Tsao AS, Harun N, Lee JJ, Heymach J, Pisters K, Hong WK, Fujimoto J, Wistuba I. Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Chemonaive Patients With Unresectable Malignant Pleural Mesothelioma. Clin Lung Cancer 15(3):197-201, 2014. e-Pub 2014. PMID: 24492162.
119. Tsao AS. The Evolution of Targeted Therapy in Non-small cell Lung Cancer. Foundations of Clinical Cancer Research Newsletter, 2014. e-Pub 2014.
120. Massarelli E, Papadimitrakopoulou V, Welsh J, Tang C, Tsao AS. Immunotherapy in Lung Cancer. Transl Lung Cancer Res 3(1):53-63, 2014. e-Pub 2014. PMID: 25806281.
121. Blumenschein GR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) trial. Clin Cancer Res 19(24):6967-75, 2013. e-Pub 2013. PMID: 24166906.
122. Gomez D, Tsao AS, Rice D. Recurrence of malignant pleural mesothelioma at the resection borders--local or distant recurrence?. J Thorac Oncol 8(7):e65-6, 2013. e-Pub 2013. PMID: 23774390.
123. Tsao AS, Papadimitrakopoulou V. The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results. Clin Lung Cancer 14(4):311-21, 2013. e-Pub 2013. PMID: 23582282.
124. Tsao AS, Hui EP, Juergens R, Marur S, Huat TE, Cher GB, Hong RL, Hong WK, Chan AT. Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer. Cancer Med 2(3):351-9, 2013. e-Pub 2013. PMID: 23930212.
125. Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol 8(5):658-61, 2013. e-Pub 2013. PMID: 23584298.
126. Tam AL, Kim ES, Lee JJ, Ensor JE, Hicks ME, Tang X, Blumenschein GR, Alden CM, Erasmus JJ, Tsao AS, Lippman SM, Hong WK, Wistuba II, Gupta S. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol 8(4):436-42, 2013. e-Pub 2013. PMID: 23442309.
127. Falchook GS, Janku F, Tsao AS, Bastida CC, Stewart DJ, Kurzrock R. Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. J Thorac Oncol 8(2):e19-20, 2013. e-Pub 2013. PMID: 23328556.
128. Gomez DR, Hong DS, Allen PK, Welsh JS, Mehran RJ, Tsao AS, Liao Z, Bilton SD, Komaki R, Rice DC. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol 8(2):238-45, 2013. e-Pub 2013. PMID: 23247629.
129. Tsao AS. Mesothelioma. J Thorac Oncol 7(16 Suppl 5):S399-400, 2012. e-Pub 2012. PMID: 23160333.
130. Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol 7(11):1645-52, 2012. e-Pub 2012. PMID: 23059780.
131. Amini A, Correa AM, Komaki R, Chang JY, Tsao AS, Roth JA, Swisher SG, Rice DC, Vaporciyan AA, Lin SH. The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy. Ann Thorac Surg 94(3):914-20, 2012. e-Pub 2012. PMID: 22819472.
132. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao AS, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: Implications for signaling and clinical outcome. J Natl Cancer Inst 104(3):228-39, 2012. e-Pub 2012. PMID: 22247021.
133. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol 6(12):2104-11, 2011. e-Pub 2011. PMID: 21892101.
134. Tsao AS, Garland L, Redman M, Kernstine K, Gandara D, Marom EM. Reply to the Letter of the Editor entitled A Practical Guide to Measure "All" Malignant Pleural Mesothelioma Tumors by Modified RECIST Criteria?. J Thor Oncol 6(12):2144-5, 2011. e-Pub 2011. PMID: 22198493.
135. Garland LL, Chansky K, Wozniak AJ, Tsao AS, Gadgeel SM, Verschraegen CF, Dasilva MA, Redman M, Gandara DR. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol 6(11):1938-45, 2011. e-Pub 2011. PMID: 21964533.
136. Tsao AS, Heymach J. Mesothelioma and small cell lung cancer. J Thorac Oncol 6(11 Suppl 4):S1825-6, 2011. e-Pub 2011. PMID: 22005546.
137. Tsao AS, Wei W, Kuhn E, Spencer L, Solis LM, Suraokar M, Lee JJ, Hong WK, Wistuba II. Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-β) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. Clin Lung Cancer 12(6):369-74, 2011. e-Pub 2011. PMID: 21729646.
138. Tsao AS, Papadimitrakopoulou V. Mitotic inhibitors. J Thorac Oncol 6(11 Suppl 4):S1789-90, 2011. e-Pub 2011. PMID: 22005531.
139. Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao AS, Gillin M, Mohan R, Cox JD. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer 117(20):4707-13, 2011. e-Pub 2011. PMID: 21437893.
140. Sejpal S, Komaki R, Tsao AS, Chang JY, Liao Z, Wei X, Allen PK, Lu C, Gillin M, Cox JD. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer 117(13):3004-13, 2011. e-Pub 2011. PMID: 21264827.
141. Tsao AS, Papadimitrakopoulou VA. The future of NSCLC: molecular profiles guiding treatment decisions. Oncology (Williston Park) 25(7):607, 614, 2011. e-Pub 2011. PMID: 21888260.
142. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao AS, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The Battle Trial: Personalizing Therapy for Lung Cancer. Cancer Discov 1(1):44-53, 2011. e-Pub 2011. PMID: 22586319.
143. Tsao AS, Garland L, Redman M, Kernstine K, Gandara D, Marom EM. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J Thorac Oncol 6(3):598-601, 2011. e-Pub 2011. PMID: 21270668.
144. Garland L, Flores R, Tsao AS. Individualizing mesothelioma treatment: small steps into a brighter future. Clin Lung Cancer 11(6):371-3, 2010. e-Pub 2010. PMID: 21062727.
145. Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 69(3):337-40, 2010. e-Pub 2010. PMID: 20036440.
146. Dayyani F, Etzel C, Liu M, Chung-Han H, Lippman S, Tsao AS. Meta-analysis of the impact of human papilomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head and Neck Oncology 2(15), 2010. e-Pub 2010. PMID: 20587061.
147. Tsao AS. Cetuximab combined with chemotherapy in NSCLC. Community Oncology 7(1):17-22, 2010. e-Pub 2010.
148. Tsao AS, Roth JA, Herbst RS. Future directions in multimodality therapy for III A NSCLC: Intergroup Trial 0139. Nat Rev Clin Oncol 7(1):10-12, 2010. e-Pub 2010. PMID: 20029443.
149. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) 2(11):931-941, 2009. e-Pub 2009. PMID: 19892663.
150. Ivanova AV, Ivanov SV, Prudkin L, Nonaka D, Liu Z, Tsao AS, Wistuba I, Roth J, Pass HI. Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer 8:91, 2009. e-Pub 2009. PMID: 19852844.
151. McAleer MF, Tsao AS, Liao Z. Radiotherapy in malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 75(2):326-37, 2009. e-Pub 2009. PMID: 19735859.
152. Tsao AS. Novel Therapies in metastatic HNSCC. Community Oncology 6(7):310-316, 2009. e-Pub 2009.
153. Salmon S, Chen H, Chen S, Herbst R, Tsao AS, Tran H, Sandler A, Billheimer D, Shyr Y, Lee JW, Massion P, Brahmer J, Schiller J, Carbone D, Dang TP. Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol 4(6):689-696, 2009. e-Pub 2009. PMID: 19404214.
154. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant Pleural Mesothelioma. J Clin Oncol 27(12):2081-90, 2009. e-Pub 2009. PMID: 19255316.
155. Tsao AS, Mehran R, Roth JA. Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma. Clin Lung Cancer 10(1):36-41, 2009. e-Pub 2009. PMID: 19289370.
156. Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao AS, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma BAC subtype predict response to erlotinib. J Clin Oncol 26(9):1472-1478, 2008. e-Pub 2008. PMID: 18349398.
157. Rice DC, Stevens CW, Correa AM, Vaporciyan AA, Tsao AS, Forster KM, Walsh GL, Swisher SG, Hofstetter WL, Mehran RJ, Roth JA, Liao Z, Smythe WR. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 84(5):1685 - 1692, 2007. e-Pub 2007. PMID: 17954086.
158. Carbone M, Albelda S, Boaddus V, Flores R, Hillerdal G, Jaurand M, Kjaerheim K, Pass H, Robinson B, Tsao AS. Eighth International Mesothelioma Interest Group. Oncogene 26(49):1685-1692, 2007. e-Pub 2007. PMID: 17496929.
159. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 6(7):1962-1970, 2007. e-Pub 2007. PMID: 17620427.
160. Tsao AS, Ensley J, Hong WK, El-Naggar AK, Papadimitrakopoulou V. Successful Biochemoprevention in a patient with multiple aerodigestive malignancies. International Journal of Cancer Prevention 2(4):297-300, 2007. e-Pub 2007.
161. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 24(25):4163-9, 2006. e-Pub 2006. PMID: 16943532.
162. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 106(11):2428-36, 2006. e-Pub 2006. PMID: 16634096.
163. Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba I. Clinical-Pathological Characteristics of the EGFR Gene Mutation in Non-small Cell Lung Cancer. J Thorac Oncol 1(3):231-239, 2006. e-Pub 2006. PMID: 17409862.
164. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 7(5):326-331, 2006. e-Pub 2006. PMID: 16640804.
165. Rice DC, Erasmus JJ, Stevens CW, Vaporciyan AA, Wu JS, Tsao AS, Walsh GL, Swisher SG, Hofstetter WL, Ordonez NG, Smythe WR. Extended Surgical Staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg 80(6):1988-1992, 2005. e-Pub 2005. PMID: 16305830.
166. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao AS, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23(11):2544-55, 2005. e-Pub 2005. PMID: 15753462.
167. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Letter to the Editor: STI-571 causes hypopigmentation in the skin. Cancer 100(11):2487-2488, 2004. e-Pub 2004. PMID: 14635084.
168. Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin 54(3):150-180, 2004. e-Pub 2004. PMID: 15195789.
169. Tsao AS, Shin DM, Palmer JL, Lee JS, Glisson BS. Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. Cancer 100(10):2240-5, 2004. e-Pub 2004. PMID: 15139070.
170. Tsao AS, Kantarjian H, Thomas D, Giles F, Cortes J, Garcia-Manero G, Huh Y, Yang Y, Shen Y, Albitar M, Estey E. C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res 28(4):373-8, 2004. e-Pub 2004. PMID: 15109537.
171. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. STI-571 induced hypopigmentation in CML patients. Cancer 98(11):2483-7, 2003. e-Pub 2003. PMID: 14635084.
172. Karp DD, Tsao AS, Kim ES. Nonsmall-cell lung cancer: chemoprevention studies. Semin Thorac Cardiovasc Surg 15(4):405-20, 2003. e-Pub 2003. PMID: 14710383.
173. Tsao AS, McDonnell T, Lam S, Putnam JB, Bekele N, Hong WK, Kurie JM. Increased phospho-AKT (Ser473) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 12(7):660-664, 2003. e-Pub 2003. PMID: 12869408.
174. Tsao AS, Kim ES. Salvage therapies for Non-small cell lung cancer. Oncology Special Edition 6:167-170, 2003. e-Pub 2003.
175. Tsao AS, Herbst R. Factors that determine response to EGFR inhibitors. Signal 4(4):4-9, 2003. e-Pub 2003.
176. Tsao AS, Garey JS, An K, Kim ES. Understanding and managing toxicities related to EGFR inhibitors. EGFR in Oncology 1(1):8-10, 2003. e-Pub 2003.
177. Tsao AS, Kantarijian H, Talpaz M. STI-571 in chronic myelogenous leukaemia. Br J Haematol 119(1):15-24, 2002. e-Pub 2002. PMID: 12358949.
178. Kim ES, Tsao, AS. Novel Therapeutics in Non-Small Cell Lung Cancer. Lung Cancer Updates 3(4):1-20, 2002. e-Pub 2002.
179. Tsao AS, Roth LM, Sandler A, Hurteau JA. Cervical primitive neuroectodermal tumor. Gynecol Oncol 8(1):138-42, 2001. e-Pub 2001. PMID: 11585426.
180. Tsao AS, Tsao KY. Silicon Pressure Applications in the Medical Field. Industrial Materials, Taiwan 121:113-126, 1997. e-Pub 1997.

Professional Educational Materials

1. Tsao A, Vogelzang N. UptoDate: Systemic treatment for unresectable malignant pleural mesothelioma. UptoDate, 2022.
2. Pass H, Tsao A, Rosenzweig K. UptoDate: Initial Management of malignant pleural mesothelioma. UptoDate, 2022.
3. Pass H, Tsao A, Rosenzweig K. UptoDate: Initial Management of malignant pleural mesothelioma. UptoDate, 2021.
4. Tsao A, Vogelzang N. UptoDate: Systemic treatment for unresectable malignant pleural mesothelioma. UptoDate, 2021.
5. Tsao A, Vogelzang N. UptoDate: Systemic treatment for unresectable malignant pleural mesothelioma. UptoDate, 2020.
6. Pass H, Tsao A, Rosenzweig K. UptoDate: Initial Management of malignant pleural mesothelioma. UptoDate, 2020.
7. Tsao A, Vogelzang N. UptoDate: Systemic treatment for unresectable malignant pleural mesothelioma. UptoDate, 2019.
8. Tsao A, Vogelzang N. UptoDate: Systemic treatment for unresectable malignant pleural mesothelioma. UptoDate, 2018.
9. Tsao A, Vogelzang N. UptoDate: Systemic treatment for unresectable malignant pleural mesothelioma. UptoDate, 2017.
10. Tsao A, Vogelzang N. UptoDate: Systemic treatment for unresectable malignant pleural mesothelioma. UptoDate, 2016.
11. Tsao A, Vogelzang N. UptoDate: Systemic treatment for unresectable malignant pleural mesothelioma. UptoDate, 2015.
12. Gandara D, Langer C, Patel J, Sequist L, Tsao AS, Weiss J. ASCO Lung Cancer MOC Course. ASCO University, 2015.
13. Tsao A, Vogelzang N. UptoDate: Systemic treatment approaches for malignant mesothelioma. UptoDate, 2014.
14. Tsao A, Vogelzang N. UptoDate: Systemic treatment for unresectable malignant pleural mesothelioma. UptoDate, 2013.
15. Tsao AS. OncoFacts IASLC 2013. IASLC, 2013.
16. Tsao AS, Lin-Chi C, Vogelzang N. UptoDate: Systemic treatment approaches for malignant mesothelioma. UptoDate, 2012.
17. Tsao AS. Pearls of Wisdom: Malignant Pleural Mesothelioma. The ASCO Post, 2012.
18. Tsao AS. Treatment of Lung Cancer. Merck & Co, 2012.
19. Tsao AS. ASCO Literature Reviews, 2011-2014. ASCO University, 2011.
20. . Global Resource for Advancing Cancer Education: Update on Mesothelioma. GRACE, 2010.
21. Tsao AS, Hong WK. Treatment of Lung Cancer. Merck & Co, 2008.
22. Tsao AS, Hong WK. Treatment of Lung Cancer. Merck & Co, 2006.

Abstracts

1. Scherpereel A, Fennell DA, Fujimoto N, Marmarelis ME, Tsao A, Aerts J, Li X, Dalvi T, Jiang H, Krug L, Zauderer MG. eVOLVE-Meso: A global phase 3 study of first-line volrustomig plus chemotherapy in unresectable pleural mesothelioma. 2025 IASLC WCLC Annual Meeting, 2025. e-Pub 2025.
2. French KE, Bickel J, Renna V, Kheirkhah P, Taiwo V, Tsao AS, Adelson KB. Streamlining workflows and optimizing the EHR: Ease of practice project started at a comprehensive cancer center with aims to enhance professional fulfillment. 2025 ASCO Quality Care Symposium 21(Suppl 10), 2025. e-Pub 2025.
3. Lin SH, Tsao AS, Edelman MJ, Doemer AJ, Simone CB, II, Valle DM, Roudko V, Nie K, Rizakos T, Mugunthan A, Zhang R, Kelly G, Beckman N, Thompson RC, Suarez-Farinas M, Gnjatic S, Kim-Schulze S, Gonzalez-Kozlova E, Gandhi S, Bikkina S, Karim N, Shen X, Badiyan S, Higgins K, Chakravarti A, Werner-Wasik M, Schallenkamp JM, Pugh S, Bradley JD. Safety and Biomarker Analysis of NRG-LU004: Phase I Trial of Radiotherapy With Durvalumab in PD-L1 High LA-NSCLC. 2025 IASLC WCLC Annual Meeting 20(10):S350-S351, 2025. e-Pub 2025.
4. Aggarwal C, Stevenson J, Kowalski DM, Csőszi T, Peled N, Cho BC, Rubio-Viqueira B, Niu J, Carbone DP, Arnold SM, Awad MM, Gainor JF, Rao S, Tsao AS, Zhou H, Akala OO, Chartash E, Nadal E. Results from KEYMAKER-U01 substudy 3: a phase 2 umbrella study of pembrolizumab plus investigational agents in patients with non-small-cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy. 2024 AACR Annual Meeting 84(Suppl 7), 2024. e-Pub 2024.
5. Tsao AS, Hsieh M, Koczywas M, Tu JC, Riess JW, Tanvetyanon T, Ma BT, Zhao Y, Redman MW, Edelman MJ, Gandara DR, Kelly K, Gray JE. S1701: A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma. 2024 ASCO Annual Meeting 42(Suppl 16), 2024. e-Pub 2024.
6. Smit E, Ahn M, Dagogo-Jack I, Felip E, Gelsomino F, Johnson BE, Johnson M, Negrao MV, Offin M, Ramalingam S, Sanborn R, Tsao A, Wilner K, Alcasid A, Usari T, Zhang X, Riely G. Updated safety analysis of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC from PHAROS study. 2024 IASLC WCLC Annual Meeting, 2024. e-Pub 2024.
7. Heeke S, Gandhi S, Tran HT, Lam V, Byers LA, Gibbons DL, Gay CM, Altan M, Antonoff MB, Le X, Tu J, Pek M, Poh J, Ngew KC, Tsao A, Cascone T, Negrao M, Jr BG, Heymach JV, Elamin YY. Longitudinal tracking of ALK-positive lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA in the BRIGHTSTAR clinical trial. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
8. Szlosarek PW, Creelan B, Sarkodie T, Nolan L, Taylor P, Olevsky O, Grosso F, Cortinovis D, Chitnis M, Roy A, Gilligan D, Kindler H, Papadatos-Pastos D, Ceresoli GL, Mansfield A, Tsao A, O’Byrne K, Nowak AK, Steele J, Sheaff M, Johnston A, Bomalaski J, Zauderer M, Fennell DA. Phase 2-3 trial of pegargiminase plus chemotherapy versus placebo plus chemotherapy in patients with non-epithelioid pleural mesothelioma. 2023 AACR Annual Meeting 83(Suppl 8), 2023. e-Pub 2023.
9. Aminu M, Vokes NI, Saad MB, Li H, Hong L, Mohamed MS, Boom J, Chen P, Altan M, Gandhi S, Swisher S, Antonoff MB, Pozadzides JV, Jr GB, Gibbons DL, Cascone T, Elamin YY, Le X, Negrao MV, Skoulidis F, Tsao AS, Tu J, Lee J, Zhang J, Heymach JV, Wu J. Tumor volumetric analysis to correlate disease burden with response to dual immune checkpoint blockade in metastatic NSCLC. 2023 AACR Annual Meeting 83(Suppl 7), 2023. e-Pub 2023.
10. Forde PM, Forde PM, Nowak AK, Nowak AK, Hughes BGM, Hughes BGM, Kok PS, Kok PS, Brown C, Brown C, Sun Z, Sun Z, Anagnostou V, Anagnostou V, O'Byrne K, O'Byrne K, Yip S, Yip S, Cook A, Cook A, Lesterhuis WJ, Lesterhuis WJ, Pavlakis N, Pavlakis N, Brahmer JR, Brahmer JR, Kindler HL, Kindler HL, Tsao AS, Tsao AS, Zauderer MG, Zauderer MG, Ramalingam SS, Ramalingam SS, Stockler MR, Stockler MR. DuRvalumab with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial. The DREAM3R trial. 2023 ASCO Annual Meeting 41(Suppl 16), 2023. e-Pub 2023.
11. Chang JY, Lin SH, Dong W, Liao Z, Gandhi S, Chun SG, Gay CM, Zhang J, Fossella FV, Blumenschein GR, Cascone T, Le X, Pozadzides JV, Tsao A, Mehmet A, Welsh JW, Verma V, Wistuba II, Lee J, Heymach J. Randomized Phase II Study Comparing Stereotactic Ablative Radiotherapy with or Without Immunotherapy for Early-Stage or Isolated Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR Trial. 2023 IASLC WCLC Annual Meeting 18(Suppl 11):S71, 2023. e-Pub 2023.
12. Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao AS, Johnson ML, Gelsomino F, Esper RM, Nadal E, Offin M, Provencio-Pulla M, Otterson GA, Dagogo-Jack I, Alcasid A, Usari T, Wilner KD, Pathan N, Johnson BE. Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
13. Clemens MW, Fracol M, Rodriguez MM, Tsao AS. Implant Associated Squamous Cell Carcinoma: An Emerging Chest Wall Malignancy. 2023 IASLC WCLC Annual Meeting 18(11):S722–S723, 2023. e-Pub 2023.
14. Lin SH, Pugh SL, Tsao AS, Edelman MJ, Doemer A, Charles B Simone II, Gandhi S, Bikkina S, Abdel Karim NF, Shen X, Badiyan SN, Higgins KA, Chakravarti A, Werner-Wasik M, Schellenkamp JM, Paulus R, Bradley JD. Safety results of NRG-LU004: Phase I trial of accelerated or conventionally fractionated radiotherapy combined with durvalumab in PD-L1–high locally advanced non-small cell lung cancer. 2022 ASCO Annual Meeting 40(Suppl 16), 2022. e-Pub 2022.
15. Elamin YY, Negrao MV, Fossella FV, Byers LA, Zhang J, Gay CM, Tu JC, Pozadzides JV, Tran HT, Lu C, Feng L, Spelman AR, Blumenschein GR, Tsao AS, Heymach J. Results of a phase 1b study of osimertinib plus sapanisertib or alisertib for osimertinib-resistant, EGFR-mutant non–small cell lung cancer (NSCLC). 2022 ASCO Annual Meeting 40(Suppl 16), 2022. e-Pub 2022.
16. Tsao AS, Song Z, Ho AL, Mehnert JM, Mitchell EP, Wright JJ, Takebe N, Gray RJ, Wang V, McShane L, Rubinstein LV, Patton DR, Williams P, Hamilton SR, Conley BA, Arteaga CL, Harris L, O’Dwyer PJ, Chen AP, Flaherty K. Phase II study of vismodegib in patients with SMO or PTCH1 mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T. 2022 ASCO Annual Meeting 40(Suppl 16), 2022. e-Pub 2022.
17. Hui D, Puac V, Shelal Z, Dev R, Hanneman S, Jennings K, Ma HY, Urbauer DL, Shete S, Fossella FV, Liao ZX, Blumenschein GR, Chang JY, O'Reilly M, Gandhi S, Tsao AS, Mahler D, Bruera E. Alleviating breathlessness in patients with cancer with dexamethasone (ABCD): A parallel-group, double-blind, randomized clinical trial (RCT). 2022 ASCO Annual Meeting 40(Suppl 16), 2022. e-Pub 2022.
18. Altan M, Sui D, Gandhi S, Swisher S, Vokes NI, Antonoff M, Zhang J, Blumenschein GR, Cascone T, Elamin YY, Gay CM, Gibbons DL, Le X, Negrao MV, Skoulidis F, Tsao AS, Tu JC, Spelman AR, Lee J, Heymach J. Clinical outcome and potential benefits of post-progression immunotherapy for patients with metastatic NSCLC with primary resistance to ipilumumab and nivolumab in the LONESTAR phase III study. 2022 ASCO Annual Meeting 40(Suppl 16), 2022. e-Pub 2022.
19. Le X, Wang R, Vokes N, Elamin Y, Kalhor N, McGrail D, Xi Y, Santiago Treviño III, Hong L, Du R, Blumenschein G, Gay C, Negrao M, Altan M, Tran H, Hu L, Wang J, Heeke S, Nilsson M, Robichaux J, Dang M, Han G, Byers L, Tsao A, Sepesi B, Bernatchez C, Zhang J, Wang L, Heymach J. Enhanced lineage plasticity in RTK-independent TKI-resistant EGFR-mutant NSCLC. 2022 AACR Annual Meeting 82(Suppl 12), 2022. e-Pub 2022.
20. Forde PM, Nowak AK, Kok P, Brown C, Sun Z, Anagnostou V, O'Byrne KJ, Yip S, Cook A, Lesterhuis WJ, Maxwell Hughes BG, Pavlakis N, Brahmer JR, Kindler HL, Tsao AS, Zauderer MG, Ramalingam SS, Stockler MR. DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial. 2022 ASCO Annual Meeting 40(Suppl 16), 2022. e-Pub 2022.
21. Chapman LO, Overman MJ, Willett A, Knafl M, Fu S, Malpica A, Scally C, Mansfield PF, Matamoros Jr AA, Morani A, Woodman SE, Sepesi B, Mehran RJ, Haymaker CL, Varadhachary GR, Tsao AS, Fournier K, Raghav KP. Comprehensive genomic profiling of malignant peritoneal mesothelioma (MPeM) reveals key genomic alterations (GAs) distinct from malignant pleural mesothelioma (MPM). 2021 ASCO Annual Meeting 39(Suppl 15), 2021. e-Pub 2021.
22. Forde PM, Nowak AK, Kok P, Brown C, Sun Z, Anagnostou V, O'Byrne KJ, Yip S, Cook A, Lesterhuis WJ, Hughes BG, Pavlakis N, Brahmer JR, Kindler HL, Tsao AS, Zauderer MG, Ramalingam SS, Stockler MR. DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial. 2021 ASCO Annual Meeting 39(Suppl), 2021. e-Pub 2021.
23. Zhou N, Sepesi B, Leung CH, Lin HY, William Jr WN, Weissferdt A, Pataer A, Godoy M, Fossella FV, Jr GB, Le X, Tsao AS, Zhang J, Hofstetter WL, Swisher S, Vaporciyan AA, Lee J, Gibbons DL, Heymach J, Cascone T. Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study. 2021 ASCO Annual Meeting 39, 2021. e-Pub 2021.
24. Reuss JE, Sepesi B, Rolfo CD, Zahurak M, Anagnostou V, Smith KN, Cottrell T, Stein JE, Illei PB, Taube JM, Rosner GL, Murray JC, Nakajima EC, Voong K, Hales RK, Yang S, Battafarano RJ, Friedberg J, Tsao AS, Forde PM. Trial in progress: Neoadjuvant immune checkpoint blockade in resectable malignant pleural mesothelioma. 2020 ASCO Virtual Scientific Program 38(Suppl), 2020. e-Pub 2020.
25. Adams DL, He J, Qiao Y, Gardner KP, Haymach JV, Tsao AS, Raghavakaimal A, Tang C, Augustyn A, Lin SH. Expression of pd-l1 on circulating stromal cells predicts immunotherapy response in unresectable non-small cell lung carcinoma after definitive chemoradiotherapy. 2020 AACR Annual Meeting 80(Suppl 16), 2020. e-Pub 2020.
26. Elamin Y, Gandhi S, Antonoff M, Mott F, Gibbons DL, Le X, Negrao MV, Sepesi B, Karam JA, Cascone T, Wang L, Jr GB, Glisson BS, Tsao AS, Heymach J. BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naïve ALK-rearranged advanced NSCLC. 2020 ASCO Virtual Scientific Program 38(Suppl), 2020. e-Pub 2020.
27. Milbury K, Durrani S, Liao ZX, Yang C, Tsao AS, Cohen L, Bruera E. Controlled Trial a Couple-based meditation intervention for patients with metastatic lung cancer and their partners. 2019 Supportive Care in Oncology Symposium 37(31 Suppl), 2019. e-Pub 2019.
28. Hui D, Larsson L, Thomas S, Harrison C, Wu J, Mahler D, Hess KR, Lopez-Mattei J, Thompson K, Gomez DR, Jeter M, Lin SH, Tsao AS, Eapen G, Basen-Engquist K, Bruera E. Effect of high flow oxygen on exertional dyspnea in cancer patients: A double-blind randomized clinical trial. 2019 ASCO Annual Meeting 37, 2019. e-Pub 2019.
29. Tsao A, Qian L, Cetnar J, Sepesi B, Gomez D, Wrangle J, Simon G, Mott F, Hall R, Santana-Davila R, Koczywas M, Redman M, Kelly K. S1619 A Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and Maintenance for Resectable Pleural Mesothelioma. 2019 IASLC WCLC Annual Meeting 16(10):S870, 2019. e-Pub 2019.
30. Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Hu S, Elamin Y, Le X, Goldberg ME, Wu CJ, Zhang J, Barreto DS, Rinsurongkawong W, Simon GR, Roth J, Swisher S, Lee J, Tsao AS, Papadimitrakopoulou V, Gibbons DL, Glisson B, Miller VA, Alexander B, Frampton MG, Albacker LA, Shames DS, Zhang J, Heymach JV. BRAF Mutations Are Associated with Increased Benefit from PD1/PDL1 Blockade Compared with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. 2019 IASLC WCLC Annual Meeting 14(10 Suppl):S257-S258, 2019. e-Pub 2019.
31. Lin SH, Lin Y, Mok I, Young JA, Phan S, Sandler A, Papadimitrakopoulou V, Heymach J, Tsao AS. Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer. 2019 ASCO Annual Meeting 37(Suppl), 2019. e-Pub 2019.
32. Janne PA, Neal JW, Camidge D, Spira AI, Piotrowska Z, Horn L, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West H, Vincent S, Zhu J, Li S, Riely GJ. Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. 2019 ASCO Annual Meeting 37(Suppl), 2019. e-Pub 2019.
33. Moding EJ, Liu Y, Nabet B, Chabon JJ, Chaudhuri A, Hui AB, He J, Qiao Y, Heymach J, Tsao AS, Liao ZX, Gomez DR, Ramchandran K, Neal JW, Wakelee HA, Loo BW, Lin SH, Alizadeh AA, Diehn M. ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer. 2019 ASCO Annual Meeting 37(Suppl), 2019. e-Pub 2019.
34. Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach J, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel SM, Redman MW, Gandara DR, Kelly K. SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma. 2018 ASCO Annual Meeting 36(Suppl), 2018. e-Pub 2018.
35. Cascone T, Sepesi B, Lin HY, Kalhor N, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott F, Simon GR, Antonoff M, Mehran RJ, Rice DC, Vaporciyan AA, Godoy M, Lee J, Swisher S, William Jr WN, Heymach J. A phase I study of neoadjuvant cisplatin (C), docetaxel (D) and nintedanib (N) for resectable non-small cell lung cancer (NSCLC). 2018 ASCO Annual Meeting 36(Suppl), 2018. e-Pub 2018.
36. Jalali A, Wang J, Lee W, Zhang J, Wu CC, Gibbons DL, Tang X, Kalhor N, Izzo J, Behrens C, V Fossella FV, Tsao AS, Lee J, Swisher S, Heymach J, Futreal A, Wistuba II, Herbst RS, Papadimitrakopoulou V, Zhang J. Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data. 2017 ASCO Annual Meeting 35(Suppl), 2017. e-Pub 2017.
37. Tang C, Heymach JV, Reuben A, Tran H, Welsh JW, Wargo J, Liao Z, Tsao AS, Prado E, Swisher SG, Zhang J, Gomez DR. Correlative analysis of systemic markers from a randomized trial assessing local consolidative therapy for non-small cell lung cancer (NSCLC) patients with oligometastatic disease. 2017 AACR Annual Meeting 77(Suppl 13), 2017. e-Pub 2017.
38. Tran H, Zhang J, Vasquez M, Fossella F, Simon G, Tsao A, Gibbons DL, Elamin Y, Banks K, Lanman R, Papadimitrakopoulou V, Heymach J. Retrospective Review Clinical Use of a cfDNA Blood Test for Identification of Targetable Molecular Alterations in Patients with Lung Cancer. 2017 WCLC Annual Meeting 12(Suppl 1):S952, 2017. e-Pub 2017.
39. Tsao AS, Wistuba II, Xia D, A Byers LA, Diao L, Wang J, Papadimitrakopoulou V, Tang X, Lu W, Kadara H, H Gumus ZH, Tan Z, Zhang S, B Nilsson MB, Heymach J. Response of germline and somatic smoothened (SMO) mutations in non-small cell lung cancer (NSCLC) to hedgehog inhibitor vismodegib. 2017 ASCO Annual Meeting 35(Suppl), 2017. e-Pub 2017.
40. Lin SH, Lin Y, Price J, Parker M, Gomez DR, Welsh JW, Komaki R, Kurie JM, Simon GR, Blumenschein Jr GR, Young JA, Phan S, Sandler A, Papadimitrakopoulou V, Heymach J, Tsao AS. DETERRED: PD-L1 blockade to evaluate the safety of lung cancer therapy using carboplatin, paclitaxel, and radiation combined with MPDL3280A (atezolizumab). 2017 ASCO Annual Meeting 35(Suppl), 2017. e-Pub 2017.
41. Loehrer PJ, Tsao AS, Radovich M, Felau I. Molecular analysis of thymic epithelial tumors (TETs): A report by The Cancer Genome Atlas (TCGA) research network. 2017 ASCO Annual Meeting 35(Suppl), 2017. e-Pub 2017.
42. Tang C, Heymach JV, Reuben A, Tran H, Welsh J, Wargo J, Liao Z, Tsao A, Prado E, Swisher S, Zhang J, Gomez D. Correlative analysis of systemic markers from a randomized trial assessing local consolidative therapy for non-small cell lung cancer (NSCLC) patients with oligometastatic disease Available. 2017 AACR Annual Meeting 17(Suppl 13), 2017. e-Pub 2017.
43. Szlosarek PW, Baas P, Ceresoli GL, Fennell DA, Gilligan D, Johnston A, Lee P, Mansfield AS, Nolan L, Nowak AK, Steele JPC, Taylor P, Tsao AS, Zauderer MG, Bomalaski JS. ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma. 2017 ASCO Annual Meeting 35(Suppl), 2017. e-Pub 2017.
44. Tran HT, Elamin Y, Simon GR, Blumenschein GR, Tsao AS, Papadimitrakopoulou V, Gibbons DL, Fossella F, Lanman RB, Banks KC, Byers L, Zhang J, Heymach J. Retrospective Review Clinical Use of a cfDNA Blood Test for Identification of Targetable Molecular Alterations in Patients with Lung Cancer. 2017 WCLC Annual Meeting 12(1), 2017. e-Pub 2017.
45. Zauderer MG, Tsao AS, Fennell DA, Wong WB, Pattipaka T, Bretscher MT, Peake M. Patterns of comorbidity, treatment, resource utilization, and referral in malignant pleural mesothelioma patients in the US. 2017 ASCO Annual Meeting 35(Suppl), 2017. e-Pub 2017.
46. Tsao AS, Wistuba II, Xia D, Byers LA, Diao L, Wang J, Papadimitrakopoulou V, Tang X, Lu W, Kadara H, Gumus ZH, Tan Z, Zhang S, Nilsson MB, Heymach AJ. Response of germline and somatic smoothened (SMO) mutations in non-small cell lung cancer (NSCLC) to hedgehog inhibitor vismodegib. 2017 ASCO Annual Meeting 35(Suppl 15), 2017. e-Pub 2017.
47. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Camidge DR, Doebele RC, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Komaki R, Louie AV, Palma DA, Tsao AS, William WN, Zhang J, Swisher S, Heymach J. Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study. 2016 ASCO Annual Meeting 34(Suppl), 2016. e-Pub 2016.
48. Kindler HL, Scherpereel A, Calabro L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Ibrahim RA, Taboada M, Puglisi M, Stockman PK, Maio M. Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study. 2016 ASCO Annual Meeting 34(Suppl), 2016. e-Pub 2016.
49. L Kindler HL, Scherpereel A, Calabrò L, Aerts J, Perez SC, Bearz A, Nackaerts K, A Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, J Antonia SJ, K Nowak AK, A Ibrahim RA, Taboada M, Puglisi M, K Stockman PK, Maio M. Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study. 2016 ASCO Annual Meeting 34(Suppl), 2016. e-Pub 2016.
50. Reck M, Paz-Ares LG, Bidoli P, Cappuzzo F, Dakhil SR, Moro-Sibilot D, Borghaei H, L Johnson ML, Jotte RM, Pennell NA, Shepherd FA, Tsao AS, Carter GC, Diehl F, Alexandris E, Lee P, Zimmermann A, Treat J, Sashegyi A, Perol M. Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC). 2016 ASCO Annual Meeting 34(Suppl), 2016. e-Pub 2016.
51. Tran HT, Tsao AS, Richardson K, Legendre B, Haider A, Davis D, Heymach J. The use of an antibody independent method, ApoStream™, to isolate circulating tumor cells (CTCs) isolated from non-small cell lung cancer patients and identification of EGFR mutations. 2015 AACR-NCI-EORTC 14(Suppl 12), 2015. e-Pub 2015.
52. Maio M, Scherpereel A, Pietro AD, Vasey P, Tsao AS, Calabrò L, Fu D, Robbins PB, Ibrahim RA, Kindler HL. Randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment of unresectable pleural or peritoneal mesothelioma. 2014 ASCO Annual Meeting 32(Suppl), 2014. e-Pub 2014.
53. Zauderer MG, Rimner A, Rosenzweig K, Wu AJ, Yorke E, Sima CS, Bhattacharjee N, Patel Z, Gomez DR, Tsao AS, Rice DC, Mehran RJ, Adusumili PS, Rusch VW, Krug LM. A multicenter phase II toxicity study of lung-sparing intensity modulated radiation therapy (IMRT) for malignant pleural mesothelioma (MPM). 2014 ASCO Annual Meeting 32(5S), 2014. e-Pub 2014.
54. Papadimitrakopoulou V, Lee J, Wistuba II, Tsao AS, Fossella FV, Heymach J, Kalhor N, Gupta S, Gettinger SN, Byers LA, Izzo J, Miller VA, Diao L, Wang J, Wei C, Coombes KR, Mauro DJ, Rubin EH, Hong WK, Herbst RS. BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC). 2014 ASCO Annual Meeting 32(Suppl 5), 2014. e-Pub 2014.
55. Weidhaas JB, Kim ES, Herbst RS, Yu J, Slack F, Blumenschein Jr GR, Tsao AS, Wistuba II, Lee J, Papadimitrakopoulou V, Hong WK, Heymach J, Tran HT. The KRAS-variant and treatment response in BATTLE-1. 2014 ASCO Annual Meeting, 2014. e-Pub 2014.
56. Chance WW, Rice DC, Allen PK, Tsao AS, Fontanilla HP, Liao Z, Chang JY, Tang C, Welsh JS, Mehran RJ, Gomez DR. Postoperative Hemithoracic Intensity Modulated Radiation Therapy (IMRT) With an Optional Integrated Boost for Malignant Pleural Mesothelioma: Toxicity, Patterns of Failure, and a Matched Survival Analysis. 2014 ASTRO Annual Meeting 90(Suppl 1), 2014. e-Pub 2014.
57. Tran HT, Legendre Jr BL, Kim ES, Blumenschein Jr GR, Tsao AS, Herbst RS, Wistuba II, Lewis M, Richardson K, Hong WK, Heymach J. The use of improved and complete enrichment co-amplification at lower denaturation temperature (ICE COLD-PCR) method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of non-small cell lung cancer (NSCLC) patients. 2014 ASCO Annual Meeting 32(5s), 2014. e-Pub 2014.
58. Zauderer MG, Dao T, Rusch VW, Ginsberg MS, Tsao AS, Panageas K, Stergiou AM, Scheinberg DA, Krug LM. Randomized phase II study of adjuvant WT1 vaccine (SLS-001) for malignant pleural mesothelioma (MPM) after multimodality therapy. 2016 ASCO Annual Meeting 34(Suppl), 2013. e-Pub 2013.
59. Tran HT, Melnikova VO, Tsao AS, Fossella FV, Johnson FM, Papadimitrakopoulou V, Garza M, Neal C, Hasegawa D, Kruempel A, Wu G, Richardson K, Lewis ME, Legendre BJ, Anderes KL, Davis DW, Heymach J. Characterization and identification of specific EGFR mutations in circulating tumor cells (CTCs) isolated from non-small cell lung cancer patients using antibody independent method, ApoStream. 2013 ASCO Annual Meeting 31(Suppl), 2013. e-Pub 2013.
60. Nguyen Q, Komaki R, Liao Z, Allen P, Gomez D, Chang JY, Crawford C, Lu C, Tsao A, Cox JD. Risk Factors Predicting Failure and Survival in Lung Cancer Patients Treated With Definitive Dose-Escalated Proton Radiation Therapy. 2013 ASTRO Annual Meeting 87(Suppl 2):S78, 2013. e-Pub 2013.
61. Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara DR. A phase I study of cediranib (NSC #732208) in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma (SWOG S0905). 2013 ASCO Annual Meeting 31(Suppl), 2013. e-Pub 2013.
62. Papadimitrakopoulou V, Wistuba II, Lee J, Tsao AS, Kalhor N, Fossella FV, Heymach J, Alden CM, Gettinger SN, Coombes KR, Saintigny P, Tang X, Duffield E, Boyer J, Davis SE, Powis G, Mauro DJ, Rubin EH, Hong WK, Herbst RS. BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC). 2013 ASCO Annual Meeting 31(Suppl), 2013. e-Pub 2013.
63. Tsao AS, Harun N, Fujimoto J, Devito V, Lee J, Mehran RJ, Hong WK, Suraokar MB, Wistuba II. Elevated PDGFRB gene copy number gain as prognostic in resected malignant pleural mesothelioma. 2012 ASCO Annual Meeting 30(Suppl), 2012. e-Pub 2012.
64. Suraokar MB, Kim D, Zhang Y, Diao L, Riquelme E, Behrens C, Mehran R, Wang J, Gazdar A, Coombes K, Tsao A, Wistuba I. Exploring the role of Twist-1 in the pathogenesis of malignant pleural mesothelioma (MPM). 2012 AACR Annual Meeting 72(Suppl 8), 2012. e-Pub 2012.
65. Garland LL, Ou S, Moon J, Mack PC, Testa J, Tsao AS, Wozniak AJ, Gandara DR. SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM). 2012 ASCO Annual Meeting 30(Suppl), 2012. e-Pub 2012.
66. Suraokar M, Coombes K, Tsao A, Wistuba I, Zhang Y, Chow C, Kim D, Diao L, Fujimoto J, Mehran R, Wang J, Behrens C. Investigating the potential of miR-203 as a therapeutic candidate and its role in the pathobiology of malignant pleural mesothelioma (MPM). 2012 AACR-IASLC The Molecular Origins of Lung Cancer 18(Suppl 3), 2012. e-Pub 2012.
67. Riquelme E, Suraokar M, Nunez M, Gazdar A, Byers L, Heymach J, Mehran R, Tsao AS, Wistuba I. Copy number gain of c-myc locus is frequently observed in malignant pleural mesothelioma with epithelioid histology. 2011 AACR Annual Meeting, 2011. e-Pub 2011.
68. Saintigny P, Diao L, Wang J, Girard L, Lin SH, Coombes KR, Liu S, Lee J, Weinstein JN, Xie Y, Fan YH, Tang XM, Kim ES, Herbst RS, Tsao A, Blumenschein GR, Mao L, Lippman SM, Minna JD, Hong WK, Wistuba II, Heymach JV. A 5-gene signature (sig) predicts clinical benefit from erlotinib in non-small cell lung cancer (NSCLC) patients (pts) harboring wild-type (wt) EGFR & KRAS. 2011 AACR Annual Meeting 71(Suppl 8), 2011. e-Pub 2011.
69. Nunez MI, Suraokar M, Behrens C, Woods DM, Lin H, Lee J, Mehran RJ, Franklin W, Tsao A, Wistuba II. Folate pathway in malignant pleural mesothelioma (MPM): Novel therapeutic opportunities due to folate receptor alpha overexpression. 2011 AACR Annual Meeting 71(Suppl 8), 2011. e-Pub 2011.
70. Ihle NT, Herbst RS, Kim ES, Wistuba II, Lee J, Blumenschein GR, Tsao AS, Chen L, Zhang S, Alden CM, Tang X, Liu S, Stewart DJ, Papadimitrakopoulou V, Heymach JV, Tran HT, Hicks ME, Erasmus JJ, Gupta S, Minna JD, Larsen J, Lippman SM, Hong WK, Powis G. Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancer Available. 2011 AACR Annual Meeting 71(Suppl 8), 2011. e-Pub 2011.
71. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II Trial of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer. 2011 IASLC Annual Meeting 6(Suppl), 2011. e-Pub 2011.
72. Krug L, Tsao A, Kass S, Rusch V, Travis W, Panageas K, Adusumili P, Kris M, Maslak P, Scheinberg D. Randomized, double-blinded, phase II trial of a WT1 peptide vaccine as adjuvant therapy in patients with malignant pleural mesothelioma (MPM). 2011 ASCO Annual Meeting 29(Suppl), 2011. e-Pub 2011.
73. Fang L, Chang JY, Komaki R, Liao Z, Kim E, Allen P, Lu C, Tsao A, Gillin M, Cox JD. Failure Patterns and Toxicity After Chemoradiation with 74 Gy(RBE) for Non-small Cell Lung Cancer. 2011 ASTRO Annual Meeting 81(2):S601-S602, 2011. e-Pub 2011.
74. Tsao A, Liu S, Lee J, Alden C, Kim E, Jr G, Herbst R, Lippman S, Wistuba I, Hong W. Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy? Subgroup analysis of clinical outcome and toxicity from the BATTLE trial. 2011 ASCO Annual Meeting 29(Suppl), 2011. e-Pub 2011.
75. Heymach JV, Saintigny P, Kim ES, Byers LA, Lee J, Coombes K, Diao L, Wang J, Tran H, Fan YH, Tsao A, Blumenschein GR, Papadimitrakopoulou VA, Tang X, Story M, Xie Y, Girard L, Weinstein J, Mao L, Minna JD, Herbst R, Lippman SM, Hong WK, Wistuba II. Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination). 2011 AACR Annual Meeting 71(Suppl 8), 2011. e-Pub 2011.
76. Tsao AS, Lin H, Lee JJ, Rice D, Vaporcyan A, Swisher S, Mehran R, Heymach JV, Wistuba II, Hong WK. Evaluation of Src Tyr419 as a predictive biomarker in a neoadjuvant trial using dasatinib in resectable malignant pleural mesothelioma. 2010 ASCO Annual Meeting 28(Suppl 15), 2010. e-Pub 2010.
77. Papadimitrakopoulou V, Guo M, Etzel C, Tsao AS, Lin H, Lee J, Holsinger F, Hong W, Sturgis EM. Human papillomavirus (HPV) transmission from oropharyngeal cancer patients to sexual partners. 2010 ASCO Annual Meeting 28(Suppl 15), 2010. e-Pub 2010.
78. Herbst RS, Blumenschien Jr GR, Kim ES, Lee J, Tsao AS, Alden CM, Liu S, Stewart DJ, Wistuba II, Hong WK. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. 2010 ASCO Annual Meeting 28(Suppl 15), 2010. e-Pub 2010.
79. Garland LL, Chansky K, Wozniak A, Tsao AS, Gadgeel S, Vershraegen C, Da Silva M, Redman M, Gandara D. SWOG S0509: A phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma. 2009 ASCO Annual Meeting 27(Suppl 15), 2009. e-Pub 2009.
80. Kim E, Herbst R, Lee J, Blumenschein G, Tsao A, Wistuba I, Alden C, Gupta S, Stewart D, K Hong AW. Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program. 2009 ASCO Annual Meeting 27(15S), 2009. e-Pub 2009.
81. Tang X, Kim E, Alden C, Gupta S, Tsao A, Blumenschein G, Liu S, Heymach J, Stewart D, Mao L, Hicks M, Lippman S, Lee J, Herbst R, Hong W, Wistuba I. Feasibility and adequacy of molecular biomarkers analysis from core needle biopsies in lung cancer: toward personalized targeted therapy development. 2009 AACR Annual Meeting 69(9), 2009. e-Pub 2009.
82. Suraokar M, Corvalan A, Chow C, Gazdar A, Moran C, Raso G, Mehran R, Tsao A, Wistuba I. Integrating microRNA and mRNA expression profiles identified a small set of unique genes up-regulated in malignant pleural mesothelioma (MPM). 2009 AACR Annual Meeting, 2009. e-Pub 2009.
83. Dayyani F, Etzel C, Liu M, Ho C, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus on cancer risk and overall survival in head and neck squamous cell carcinoma. 2009 ASCO Annual Meeting 27(Suppl 15), 2009. e-Pub 2009.
84. Tsao AS, Liu D, Lee JJ, Heymach J, Pisters K, Brewer H, Hong WK, Blumenschein G. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemo-naive patients with unresectable malignant pleural mesothelioma. 2009 IASLC Annual Meeting(Suppl), 2009. e-Pub 2009.
85. Mehran R, Gil J, Rice D, Swisher S, Lee JJ, Lippman S, Pisters K, Blumenschien G, Hong WK, Tsao AS. Phase I Trial of Neoadjuvant Dasatinib in Patients With Resectable Malignant Pleural Mesothelioma. 2009 ASCO Annual Meeting 27(Suppl 15), 2009. e-Pub 2009.
86. Suraokar M, He DD, Mendoza G, Llansa N, Woods D, Prudkin L, Wistuba I, Tsao A. High expression of epithelial-mesenchymal transition (EMT) markers in mesothelioma and possible therapeutic intervention using an N-cadherin antagonist. 2008 AACR Annual Meeting 69(Suppl 9), 2008. e-Pub 2008.
87. Salmon J, Dang T, Billheimer D, Roder H, Grigorieva J, Tsypin M, Herbst R, Tsao A, Tran H, P Carbone AD. VeriStrat predicts survival in patients with non-small celllung cancer (NSCLC) treated with erlotinib and bevacizumab. 2008 ASCO Annual Meeting 26(Suppl 15), 2008. e-Pub 2008.
88. Kim E, Kies M, Glisson B, Tsao AS, Ginsberg L, Holsinger F, Burke B, Truong M, Papadimitrakopoulou V, Lippman S. Final results of a phase II study of erlotinib,docetaxel, and cisplatin in patients with recurrent/mestastatic head and neck cancer. 2007 ASCO Annual Meeting, 2007. e-Pub 2007.
89. Tsao A, He D, Saigal B, Liu S, Lee J, Bakkannagari S, Ordonez N, Hong W, Wistuba I, Johnson AF. Activated Src kinase is expressed in malignant pleural mesothelioma tumors; dasatinib inhibition leads to cytotoxicity, cell cycle inhibition, and prevention of invasion and migration. 2007 ASCO Annual Meeting 25(18S), 2007. e-Pub 2007.
90. Miller V, Zakowski M, Riely G, Pao W, Ladanyi M, Tsao A, Sandler A, Herbst R, Kris M, Johnson D. EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC) : Results of a prospective phase II trial. 2006 ASCO Annual Meeting, 2006. e-Pub 2006.
91. Bakkannagari S, Saigal B, He D, Wistuba I, Hong WK, Johnson FM, Tsao AS. Inhibition of Src kinase in mesothelioma cell lines leads to cytotoxicity, inhibition of migration, and decreased invasion. 2006 AACR Annual Meeting 66(Suppl 8), 2006. e-Pub 2006.

Book Chapters

1. Pass HI, Carbone M, Tsao A, Rosenzweig K. Benign and Malignant Mesothelioma. In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 12th. Wolters Kluwer, 1554-1582, 2023.
2. Carbone M, Gomez D, Tsao A, Yang H, Pass H. Malignant Pleural Mesothelioma. In: Holland-Frei Cancer Medicine 10th Edition. 10th. Wiley Blackwell, 2020.
3. Tsao AS. Non–Small Cell Lung Cancer. In: The MD Anderson Manual of Medical Oncology. 3rd. McGraw-Hill Education, 2016.
4. Tsao AS, Papadimitrakopoulou V, Herbst R. Small molecule tyrosine kinase inhibitors - Causes of Cancer and Targets for Treatment. In: Molecular Oncology. Cambridge University Press, 2015.
5. Gomez DR, Tsao AS, Pass HI. Malignant Pleural Mesothelioma. In: Cancer Medicine, 2014.
6. Tsao AS, Roth J. Novel and Emerging Agents in NSCLC. In: Lung Cancer 4th edition. 4th. Wiley-Blackwell, 2014.
7. Tsao AS, Papadimitrakopoulou V, Herbst R. Section IV: Pharmacologic Targeting of Oncogenic Pathways. In: Molecular Oncology: Causes of Cancer and Targets for Treatment. Cambridge University Press, 2014.
8. Komaki R, Tsao AS, Mehran RJ. Non-Small Cell Lung Cancer. In: 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer, 45-62, 2013.
9. Tsao AS. Hematology and Oncology: Thoracic Cancer. In: Year Book of Medicine 2013. Elsevier Mosby, 131-132, 2013.
10. Tsao AS. Malignant Pleural Mesothelioma. In: The MD Anderson Manual of Medical Oncology. 2nd. McGraw-Hill, 2011.
11. McAleer M, Mehran R, Tsao AS. Mesothelioma. In: Lung Cancer: Prevention, Management, and Emerging Therapies. Spinger, 435-65, 2010.
12. Tsao AS, Papadimitrakopoulou V. Chemoprevention for Head and Neck Cancer. In: Head and Neck Cancer: A multidisciplinary Approach. 3rd. Lippincott Williams & Wilkins, 918-34, 2009.
13. Tsao AS, Kies M. Systemic Therapies for Lung Cancer. In: General Thoracic Surgery. 7th. Wolters Kluer/Lippincott Williams & Wilkins, 1497-1512, 2009.
14. Tsao AS, Stewart D. Collateral Damage Associated with Chemotherapy. In: Medical Care of Patients. BC Decker Publishing, 18-32, 2009.
15. Tsao AS. New Chemotherapies and Targeted Agents in Lung Cancer. In: Lung Cancer 3rd edition. Blackwell Publishing, 315-332, 2008.
16. Tsao AS, Glisson B. Small cell lung cancer. In: Medical Oncology: A Comprehensive Review. Medical Oncology: A Comprehensive Review, 2006.
17. Tsao AS, Kantarjian HM, Talpaz M. Chapter 8: Signal transduction inhibitors: Imatinib Mesylate. In: Drug Advances. 18th. Drug Advances, 179-204, 2003.

Books (edited and written)

1. Jack Roth, Waun Ki Hong, Ritsuko Komaki, Anne S. Tsao, Joe Chang, Shanda Blackmon. Lung Cancer. Ed(s) 4th. Wiley Blackwell.